Table 1.
Characteristics of CVID patients classified on the basis of anti S1 IgG- and IgA-antibody production following the third BNT162b2 mRNA COVID-19 vaccination dose.
| p Value | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NR n = 17 |
S1 IgG-R n = 18 |
S1 IgG/IgA-R n = 12 |
NR vs. IgG | NR vs. IgG/IgA-R | IgG vs. IgG/IgA | ||||
| Age (year), median (IQR) |
56 | (43–82) | 46 | (34–80) | 59 | (34–74) | 0.166 | 0.562 | 0.166 |
| Sex (female), n (%) |
10 | (59) | 11 | (61) | 6 | (50) | 0.485 | 1.000 | 0.421 |
| IgG (mg/dL), median (IQR) |
670 | (600–800) | 600 | (510–951) | 780 | (630–1130) | 0.023 | 0.028 | 0.023 |
| IgA (mg/dL), median (IQR) |
2 | (0–21) | 3 | (2–44) | 29 | (0–181) | 0.071 | 0.068 | 0.071 |
| IgM (mg/dL), median (IQR) |
3 | (0–142) | 13 | (2–75) | 66 | (1–117) | 0.026 | 0.906 | 0.026 |
| Lymphocytes (cells/mm3), median (IQR) |
54.5 | (20.5–74.1) | 50.9 | (27.9–73.8) | 49.8 | (1.53–70.7) | 0.954 | 0.471 | 0.47 |
| CD19+ (cells/mm3), median (IQR) |
19.8 | (1.63–83.66) | 47.1 | (11.9–161.5) | 86.86 | (22.5–208.9) | 0.0083 | <0.0001 | 0.134 |
| MBC (cells/mm3), median (IQR) |
1.52 | (0–7.5) | 6.27 | (2.4–52.2) | 37.93 | (6.45–92.18) | 0.0016 | <0.0001 | 0.0245 |
| IgM MBC (cells/mm3), median (IQR) |
1.49 | (0–7.5) | 6.08 | (2.3–44.7) | 26.1 | (3.89–73.56) | 0.0021 | <0.0001 | 0.0741 |
| Switched MBC (cells/mm3), median (IQR) |
0.01 | (0.00–0.27) | 0.15 | (0.1–5.8) | 5.36 | (1.93–16.54) | 0.0038 | <0.0001 | 0.0004 |